KPV vs BPC-157: how the research compares

What is KPV?

KPV is the tripeptide lysine, proline, valine. It forms residues 11 to 13 at the C terminus of alpha-melanocyte stimulating hormone (alpha-MSH), a 13 residue peptide cut from the precursor proopiomelanocortin. Its calculated molecular weight is about 342 g/mol. Reviews of alpha-MSH biology describe KPV as keeping most of the activity of the full hormone against inflammation while lacking its pigmentary effect, and one review noted that KPV lacks the sequence motif needed to bind any known melanocortin receptor.

The KPV literature is mostly cell and animal work. In human intestinal epithelial cells and T cells it was taken up by the PepT1 transporter and reduced NF-kappaB and MAP kinase signalling. In mice it reduced signs of colitis in several models, and in rabbits topical KPV was followed by faster closure of corneal wounds. In vitro it reduced the growth of Staphylococcus aureus and Candida albicans. No controlled human trials have been published. Our guide to KPV covers this literature in more detail.

What is BPC-157?

BPC-157 is a pentadecapeptide, a chain of 15 amino acids, with the sequence GEPPPGKPADDAGLV and a molecular weight of about 1,419 g/mol. It is described as a partial sequence of a larger protein called body protection compound, which was discovered in and isolated from human gastric juice. Its developers describe it as stable in human gastric juice. A 2012 review from the main research group, based in Zagreb, stated that a version coded PL 14736 had reached phase II clinical testing for inflammatory bowel disease, but full results of that testing do not appear in the sources reviewed here.

Most BPC-157 research is preclinical. A 2025 systematic review from an orthopaedic perspective screened 544 records and included 36 studies, of which 35 were preclinical and one was clinical. In those preclinical models BPC-157 was associated with better functional, structural and biomechanical outcomes after muscle, tendon, ligament and bone injury. The same review reported that BPC-157 is metabolised in the liver, has a half life of less than 30 minutes and is cleared by the kidneys, and that no clinical safety data were found. A separate 2025 narrative review counted only three small human pilot studies: one on knee pain, one on interstitial cystitis and one on intravenous safety. Our BPC-157 research overview covers this material in more detail.

How do they compare?

The table summarises the main differences. Evidence grades follow the scale used across these guides, where B means human case reports or at least five controlled animal studies.

Mechanisms side by side

The KPV mechanism is described mainly as an effect inside the cell. In human intestinal epithelial cells (Caco2-BBE and HT29-Cl.19A) and Jurkat T cells, KPV was carried into the cell by PepT1, a transporter for di and tripeptides that is induced in the inflamed colon. Nanomolar concentrations then reduced NF-kappaB and MAP kinase signalling and lowered cytokine release. In human bronchial epithelial cells, KPV entered the nucleus, stabilised IkappaBalpha and reduced nuclear import of the NF-kappaB subunit p65RelA. In a mouse colitis study KPV still worked in animals without functional MC1R, so its effects appear at least partly independent of the classical alpha-MSH receptor.

The BPC-157 mechanism is described mainly in terms of blood vessels and repair cells. In a study combining a chick embryo membrane assay, endothelial cell cultures and rats with hind limb ischaemia, BPC-157 increased vessel density, sped recovery of blood flow and increased the expression and internalisation of VEGFR2, with activation of the VEGFR2, Akt and eNOS pathway. In cultured rat tendon fibroblasts, BPC-157 did not directly change cell proliferation, but it increased outgrowth from tendon explants, survival under oxidative stress and cell migration, with increased phosphorylation of FAK and paxillin. Rat colon studies linked its effects to the nitric oxide system.

Put simply, the published KPV work describes a peptide that dampens one inflammatory signalling pathway, while the BPC-157 work describes a peptide associated with several repair related processes at once. Neither has a confirmed single receptor, and both mechanism pictures rest largely on work from a small number of research groups.

Research findings compared

The two peptides have rarely been studied in the same kind of model, so the comparison below is organised by research area. Each finding names the model in which it was observed.

The quality of the two records has similar limits. Both rely heavily on rodent models, and much of the BPC-157 literature comes from one group at the University of Zagreb, as the author affiliations of the rat colon studies show. The 2025 systematic review graded the BPC-157 studies it included as level IV and level V evidence, and the 2025 narrative review concluded that BPC-157 should be considered investigational until well designed clinical trials are carried out. For KPV, the key mouse colitis studies were published between 2007 and 2017 and have not been followed by human trials. In both cases, the findings below describe what was measured in a model, not an established effect.

• Intestinal inflammation, KPV: in mouse DSS colitis and T cell transfer colitis, mice that received KPV regained weight sooner and showed fewer inflammatory infiltrates and lower myeloperoxidase activity. Oral KPV in drinking water reduced DSS and TNBS colitis. Nanoparticle KPV in a hydrogel reduced DSS colitis at a far lower concentration than free peptide. In the AOM plus DSS model, KPV was followed by reduced tumour development in normal mice but not in mice lacking PepT1.
• Intestinal injury, BPC-157: in rats with cysteamine colitis and colon to colon anastomosis, animals that received BPC-157 by the intraperitoneal or oral route showed healing that controls did not show. In a rat model of ischaemic colitis, BPC-157 applied as a bath to the affected colon segment increased visible vessels and collateral connections and normalised oxidative stress markers. An older rat study reported that BPC-157 reduced cysteamine lesions in both colon and duodenum.
• Tissue repair, KPV: in rabbits with removed corneal epithelium, all eight corneas that received topical KPV were fully covered at 60 hours against none in controls, and blocking nitric oxide synthase removed the effect.
• Tissue repair, BPC-157: in rat tendon fibroblasts, BPC-157 increased explant outgrowth, migration and survival under stress. Reviews of the orthopaedic literature report improved outcomes in rat muscle, tendon, ligament and bone injury models.
• Blood vessels: BPC-157 increased vessel density and blood flow recovery in the hind limb ischaemia and chick embryo models described above. No comparable angiogenesis work on KPV was found.
• Airway and immune cells: KPV reduced NF-kappaB activity and IL8 and eotaxin release in human bronchial epithelial cells. KPV and alpha-MSH reduced the growth of Staphylococcus aureus and Candida albicans in vitro. No comparable airway or antimicrobial work on BPC-157 was found in the sources reviewed.
• Human data: no human trials of KPV were found. For BPC-157, a systematic review described a retrospective chart review of knee pain in which 7 of 12 patients reported relief lasting more than six months, with no control group. A separate pilot study gave intravenous infusions to two adults and reported no change in measured heart, liver, kidney, thyroid or glucose markers and no reported side effects. Neither report can establish efficacy or safety.

Have they been studied together?

No published study has tested KPV and BPC-157 together or compared them directly. A PubMed search combining the two names returned a single record: a 2026 review of peptides in pharmacy compounding that discusses regulatory recommendations and safety standards for a list of peptides, including both. It reports no experimental data on the two used together.

The closest overlap is that both peptides have been studied in colitis. Even there the work does not line up. KPV was studied in mice with chemically induced or T cell transfer colitis, with outcomes such as weight, myeloperoxidase activity and cytokine expression. BPC-157 was studied in rats with cysteamine colitis, ischaemic colitis and surgical anastomosis, with outcomes such as lesion healing, vessel presentation and oxidative stress markers. Differences in species, injury model, route and measurement mean the two bodies of data cannot be read against each other, and nothing in the published record describes interactions between them.

Choosing between them for a study design

The choice depends on the question being asked, not on which peptide is better. If a study is about NF-kappaB signalling, PepT1 transport, epithelial cytokine release or the activity of melanocortin fragments, KPV has the more directly relevant published work, including defined cell line systems such as Caco2-BBE, HT29-Cl.19A and 16HBE14o- cells. If a study is about fibroblast migration, endothelial tube formation, VEGFR2 signalling or rodent injury models, BPC-157 has the larger body of related work, much of it from rat tendon and gut models.

For a study that wants to compare the two in the same system, there is no published template, so the design would need to set its own baseline. Practical points include running both peptides in the same cell type with matched vehicle controls, stating the source, purity and verified mass of each peptide, and reporting concentrations in molar terms, since the molecular weights differ by more than fourfold. Shared readouts, such as NF-kappaB reporter activity, cytokine release or cell migration, would allow the results to be compared directly.

Both peptides are supplied by Vitality Peps as lyophilised 10 mg vials, and both are reconstituted with bacteriostatic water. Our storage guide and certificate of analysis guide cover preparation and documentation.

Timing is another design point. The orthopaedic systematic review reported a half life for BPC-157 of less than 30 minutes, with metabolism in the liver and clearance by the kidneys, which matters for the timing of readouts in any in vivo model. Comparable published data on the stability and clearance of free KPV are limited, and several of the stronger KPV results used nanoparticle or hydrogel carriers designed to protect and target the peptide. A study that uses free peptide should not assume that carrier based results will carry over, and may need its own stability checks in the chosen medium.

Research use only

KPV and BPC-157 supplied by Vitality Peps are for in vitro laboratory research only. Not a medicine, not a supplement, not for human or veterinary consumption. Nothing above is instructions for use.